What's Happening?
Oculis Holding AG, a biopharmaceutical company, has announced new translational biomarker data from its Phase 2 ACUITY trial for Privosegtor, a drug candidate for optic neuritis (ON). The data indicates that Privosegtor reduced post-onset increases in plasma
neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared to a placebo. These biomarkers are objective indicators of reduced neuroaxonal injury and suppressed reactive astrogliosis, respectively. The findings complement previously reported improvements in low-contrast visual acuity and preserved retinal structure at Month 3. Optic neuritis is a rare condition characterized by acute inflammation of the optic nerve, affecting over 30,000 people annually in the U.S. and often serving as an early sign of multiple sclerosis. The condition primarily affects adults between 20 and 40 years old, with a higher incidence in women.
Why It's Important?
This development is significant for the treatment of optic neuritis, a condition that can lead to permanent visual impairment and for which no approved neuroprotective therapies currently exist. The reduction in NfL and GFAP levels suggests that Privosegtor may protect retinal ganglion cells and their axons, which are crucial for transmitting visual signals. This neuroprotective potential could prevent irreversible neuro-axonal damage that can occur rapidly after ON onset. For the estimated 850,000 individuals in the U.S. living with multiple sclerosis, and the 170,000 annual MS relapses, a neuroprotective therapy like Privosegtor could significantly improve long-term outcomes and reduce disability accumulation. The drug has already received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and Orphan Drug designation from both the FDA and the European Medicines Agency (EMA), highlighting its potential to address a critical unmet medical need.
What's Next?
Oculis plans to advance Privosegtor through its PIONEER registrational program, which includes two registrational trials for ON and one for non-arteritic anterior ischemic optic neuropathy (NAION). Building on the positive Phase 2 ACUITY data and constructive feedback from the FDA, Oculis is also preparing an Investigational New Drug (IND) submission for Privosegtor for the treatment of acute multiple sclerosis relapses. The company will present the late-breaking data at the 10th Joint ACTRIMS-ECTRIMS Meeting, MSToronto 2026. If successful in further trials and regulatory approvals, Privosegtor could become the first neuroprotective therapy for optic neuropathies and potentially other neuro-axonal diseases, offering a new treatment paradigm for patients currently lacking specific therapies to prevent vision loss and nerve damage.
Beyond the Headlines
The success of Privosegtor could represent a broader shift in the treatment of neuro-ophthalmic and neuro-axonal diseases, moving beyond symptomatic relief to neuroprotection. The ability of Privosegtor to cross the blood-brain and retinal barriers is a key factor in its potential efficacy, addressing a significant challenge in drug delivery for neurological conditions. This approach could pave the way for similar neuroprotective strategies in other conditions where nerve damage is a primary driver of disability. The focus on biomarkers like NfL and GFAP also underscores the increasing sophistication of clinical trials in identifying and quantifying therapeutic effects at a molecular level, potentially accelerating drug development and approval processes for complex neurological disorders. The ethical implications of preventing irreversible damage and preserving long-term function for patients with debilitating conditions like ON and MS are profound, offering improved quality of life and reduced societal burden.
